Company Filing History:
Years Active: 2011-2014
Title: Gonzalo Alva: Innovator in Anti-Angiogenic Drug Development
Introduction
Gonzalo Alva is a notable inventor based in Moorpark, CA, who has made significant contributions to the field of pharmaceuticals. He holds 2 patents related to the anti-angiogenic drug AMG 706. His work focuses on innovative processes for drug formulation and delivery.
Latest Patents
Alva's latest patents include a process for making a solid-state form of AMG 706. This patent details the provision of AMG 706 in amorphous form, along with a drug substance where AMG 706 is present in a detectable amount. Additionally, it describes an AMG 706-crystallization inhibitor composite that includes particles of amorphous AMG 706 in association with one or more crystallization inhibitors, such as polymers. The patent also outlines a pharmaceutical composition comprising this composite and methods for preparing both the amorphous form and the crystallization inhibitor composite. Another patent focuses on hydrate forms of AMG 706, specifically the mono-phosphate hydrate form, detailing processes for preparing AMG 706 phosphate dihydrate and its pharmaceutical applications.
Career Highlights
Gonzalo Alva is currently employed at Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to contribute to the development of innovative pharmaceutical solutions that address critical medical conditions.
Collaborations
Alva has collaborated with notable colleagues, including Seshadri Neervannan and Belle Bei Liu, to advance research and development in the pharmaceutical sector.
Conclusion
Gonzalo Alva's contributions to the field of anti-angiogenic drugs through his patents and work at Amgen Inc. highlight his role as an influential inventor in the pharmaceutical industry. His innovative approaches continue to pave the way for advancements in medical treatments.